Stock ANRO ALTO NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Market Closed - Nyse
Other stock markets
 16:00:02 2024-06-14 EDT 		5-day change 1st Jan Change
12.03 USD +0.08% Intraday chart for Alto Neuroscience, Inc. +1.86% 0.00%
05-21 Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer CI
05-14 Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia
CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
MT
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder
CI
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alto Neuroscience's Shares Surge in Market Debut
MT
Alto Neuroscience Prices Upsized Initial Public Offering
MT
Alto Neuroscience, Inc. has completed an IPO in the amount of $128.64 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANRO Stock
  4. News Alto Neuroscience, Inc.
  5. Highlights